Dermata Therapeutics Enrolls 50% Of Patients In Pivotal Phase 3 STAR-1 Study For DMT310, A Novel Once-Weekly Topical Acne Treatment; Topline Results Expected In Q1 2025; Potential To Be First Once-Weekly Topical Product For Moderate-To-Severe Acne Treatment
Portfolio Pulse from Benzinga Newsdesk
Dermata Therapeutics has enrolled 50% of patients in its pivotal Phase 3 STAR-1 study for DMT310, a novel once-weekly topical acne treatment. Topline results are expected in Q1 2025, and the product has the potential to be the first once-weekly topical treatment for moderate-to-severe acne.
July 17, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dermata Therapeutics has achieved 50% enrollment in its Phase 3 STAR-1 study for DMT310, a novel once-weekly topical acne treatment. Topline results are anticipated in Q1 2025, which could make DMT310 the first once-weekly topical product for moderate-to-severe acne treatment.
The news of reaching 50% enrollment in a pivotal Phase 3 study is a significant milestone for Dermata Therapeutics. If successful, DMT310 could become the first once-weekly topical treatment for moderate-to-severe acne, potentially driving significant market interest and stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100